Compound Detail
CHEMBL6068395
REVUMENIB CITRATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O.O=C(O)CC(O)(CC(=O)O)C(=O)O
Basic Information
| ChEMBL ID | CHEMBL6068395 |
| Name | REVUMENIB CITRATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | UBXFWTFPYATLBT-SGBGZXBGSA-N |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL4650827 |
| Active Moiety | CHEMBL4650827 |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
4
Known Names
2
Indications
1
Mechanisms
Molecular Properties
630.8
MW (Da)
4.68
ALogP
8
HBA
1
HBD
108.0
PSA (Ų)
0.38
QED
1
Ro5 Violations
11
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2024 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Menin inhibitor | INHIBITOR | Menin | ✓ | ✓ |
Indications
Leukemia Neoplasms
Drug Warnings
Black Box Warning
General Warning
Data from ChEMBL 36 via Core Engine